Здравствуй ТСТ

[Abugov]

Внимание всего прогрессивного человечества приковано к Вашингтону, где проходит ТСТ.
Жгут наши китайские друзья.
Прага-5, китайский вариант:

Physician-Transfer Strategy Could Improve STEMI Outcomes

Zhang Qi, MD, and colleagues from the REVERSE-STEMI group, from Ruijin Hospital in Shanghai, China, presented their abstract at TCT 2008. They conducted a prospective, multicenter, randomized trial to assess the feasibility of transferring physicians, rather than patients, to facilitate quick and efficient PCI following ST-segment elevation myocardial infarction (STEMI).

Да и корейские ребята не отстают.
Цилостазол форева:

TRIPLE ANTIPLATELET THERAPY APPEARS SUPERIOR TO DUAL ANTIPLATELET THERAPY FOR PATIENTS UNDERGOING PCI

A collection of investigations completed in Korea examined the use of antiplatelet therapies in a variety of PCI patients including diabetics and patients with ST-segment elevation myocardial infarction (STEMI). The studies measured the overall effectiveness of triple antiplatelet therapy against the more conventional dual drug therapeutic approach and also examined the performance of the drug cilostazol in triple antiplatelet therapy. The overwhelming conclusion of these studies was that triple antiplatelet therapy for PCI patients receiving drug-eluting stents (DES) was superior to conventional dual antiplatelet therapy.

На это фоне, успехи празугреля кажутся весьма заурядными:

Analysis Confirms Speed, Efficacy of Prasugrel

Investigators from Eli Lilly and Company and Daiichi Sankyo, which are jointly developing a formulation of prasugrel for percutaneous coronary intervention, analyzed data obtained from 23 individual clinical trials involving healthy participants with stable atherosclerosis.

Researchers conducted an an integrated analysis of the previous trials, which had demonstrated previously that a 60-mg loading dose of prasugrel followed by a 10-mg daily maintenance dose produced “faster, higher and more consistent inhibition of platelet aggregation than did a clopidogrel loading dose of 300 mg followed by a 75-mg daily dose,” Grace Y. Li, MS, project statistician with Eli Lilly, said in an interview.

Ну уж, то что девушек нельзя расстраивать, мы и так подозревали:

STUDY REVEALS THAT SIGNS OF HEART DISEASE ARE ATTRIBUTED TO STRESS MORE FREQUENTLY IN WOMEN THAN MEN

[Abugov]

Шоу продолжается. Теперь все лекарства интракоронарно:

Intracoronary Abciximab Efficacious in Primary PCI
By TCT Daily Staff An intracoronary bolus of abciximab before PCI was associated with improvement in myocardial perfusion, reduction of microvascular obstruction and infarct size, and a trend toward overall improved clinical outcome compared with IV administration of the drug., …

Как обычно, мы опережаем весь мир на несколько лет. Кто-то подсмотрел наш рутинный подход:

Increased Clopidogrel May Lower Events Post-PCI in Low Responders
By TCT Daily Staff Repeated clopidogrel doses prior to PCI may safely and effectively lower the risk of adverse events after stenting in patients who are poor responders to the thienopyridine. Laurent Bonello, MD, of Hopital Universitaire Nord, Marseille, France, …

Хирурги нервно курят в сторонке:

Lower Cerebrovascular Events, Death, MI, with DES vs. CABG in Left Main Disease
By TCT Daily Staff Long term data appear to support the use of PCI instead of CABG in unprotected left main coronary artery lesions. According to a study

А также:

Stenting and CABG Equivalent for Survival in Unprotected Left Main Disease
CABG remained more effective in reducing TVR than stenting, according to three year data from the MAIN COMPARE Registry presented by Ki Bae Seung, MD, …

Ну и много других новостей. Ждём завтрашнего дня.

[Maltsev]

Ура! Есть смысл жить дальше !

--
С Уважением,
Мальцев А.А.

[Abugov]

Эх! Пробки...пробки...:

ACTION Registry: D2B Times Improving Slightly, Transfer Times Remain Poor
By TCT Daily Staff A door to balloon time of under 90 minutes was achieved in 75% of non transferred STEMI patients but in only 14% of transferred patients,

Проклятый Сайфер все ещё хорош:

Cypher, Xience Showed Less Restenosis at One Year in Asian Registry
By TCT Daily Staff Cypher (Cordis Corporation), Taxus (Boston Scientific), Endeavor (Medtronic), Genous (OrbusNeich), and Xience (Abbott Vascular) dramatically …

Продолжаем кормить плавиксом:

Dual Antiplatelet Therapy Efficacious One Year Post-DES
What started as two presentations arguing for or against continuing dual antiplatelet therapy after one year ended with both sides in agreement: Patients without contraindications to therapy should continue it indefinitely.

Аневризму чиним, на ИБС плюём:

Safe AAA Repair Possible Despite Presence of CAD
By TCT Daily Staff Abdominal aortic aneurysms can be repaired safely using endovascular or open repair in almost all patients, despite the presence of CAD